Posted inHematology-Oncology news Pediatrics
Checkpoint Inhibition Is Reshaping Pediatric Lymphoma Care, Led by Breakthroughs in Hodgkin Lymphoma and Expanding into PD-L1–Positive Non-Hodgkin Subtypes
Immune checkpoint therapy has become a major advance in pediatric Hodgkin lymphoma and is now being actively tested across selected pediatric non-Hodgkin lymphomas with strong PD-L1 biology.
